Skip to main content
SpringerLink
Log in

Vincristine Neurotoxicity

Pathophysiology and Management

  • Toxicology Management Review
  • Published:
Medical Toxicology Aims and scope Submit manuscript

Summary

Vincristine is an antineoplastic drug with a broad spectrum of activity against haematological malignancies and childhood sarcomas. Besides useful activity, it lacks the usual emetic and myelotoxicity of anticancer drugs, but its use is limited by neurotoxicity. The neurotoxicity commonly manifests as reduced motility of the intestines resulting in constipation, and peripheral neuropathy which is predominantly sensory in nature. The early symptoms include numbness and tingling of hands and feet which is accompanied by loss of deep tendon reflexes. In its more severe form, muscle weakness develops which is more marked in distal muscles of the hands and feet. Other manifestations of neurotoxicity include ocular palsies, hoarseness of voice, and autonomic neuropathy in the form of postural hypotension and atony of the urinary bladder. The neurotoxicity is dose related and cumulative with repeated dosage such that the drug therapy has to be stopped after a cumulative dose of 30 to 50mg. The neurotoxicity is usually reversible on interruption of the therapy, but the recovery is slow and takes several months. There are no specific antidotes which have established usefulness against neurotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agosti A, Bertaccini G, Paulucci R, Zanella E. Caerulein treatment for paralytic ileus. Lancet 1: 395, 1971

    Article  PubMed  CAS  Google Scholar 

  • Anderson PJ, Song SK, Slotwiner P. Fine structure of sphenomembranous degeneration of skeletal muscle induced by vincristine. Journal of Neuropathology and Experimental Neurology 26: 15–24, 1967

    Article  PubMed  CAS  Google Scholar 

  • Awida AW. Blindness and vincristine. Annals of Internal Medicine 93: 781, 1980

    Google Scholar 

  • Bradley WG. Neuropathy of vincristine in the guinea pig: an electrophysiological and pathological study. Journal of Neurological Science 10: 133–162, 1970

    Article  CAS  Google Scholar 

  • Bradley WB, Lassman LP, Pearce GW, et al. Neuropathy of vincristine in man. Journal of Neurological Science 10: 107–131, 1970

    Article  CAS  Google Scholar 

  • Burdman JA. Note of the selective toxicity of vincristine sulfate on chick-embryo sensory ganglia in tissue culture. Journal of the National Cancer Institute 37: 331–332, 1966

    PubMed  CAS  Google Scholar 

  • Casey EB, Jellife AM, LeQuesne PM, Millett YL. Vincristine neuropathy: clinical and electrophysiological observations. Brain 96: 69–86, 1973

    Article  PubMed  CAS  Google Scholar 

  • Clark JT, Karpati G, Carpenter S, et al. Effect of vincristine on skeletal muscle in the rat. Journal of Neuropathology and Experimental Neurology 31: 247–256, 1972

    Article  Google Scholar 

  • DiBella NJ. Vincristine-induced orthostatic hypotension: a prospective study. Cancer Treatment Reports 64: 359–360, 1980

    PubMed  CAS  Google Scholar 

  • Garewal HS, Dalton WS. Metoclopramide in vincristine-induced ileus. Cancer Treatment Reports 69: 1309–1311, 1985

    PubMed  CAS  Google Scholar 

  • Gottschalk PG, Dyck PJ, Kiely JM. Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 18: 875–882, 1968

    Article  PubMed  CAS  Google Scholar 

  • Grinberg R, Nemoto T, Dao TL. Vincristine (NSC-67574): dosage and response in advanced breast cancer. Cancer Chemotherapy Reports 45: 57–61, 1969

    Google Scholar 

  • Hancock BW, Naysmith A. Vincristine-induced autonomic neuropathy. British Medical Journal 207: July 26, 1975

  • Hildebrand J, Kenis Y. Additive toxicity of vincristine and other drugs for the peripheral nervous system. Acta Neurology Belgium 71: 486–491, 1971

    CAS  Google Scholar 

  • Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Research 33: 1258–1264, 1973

    PubMed  CAS  Google Scholar 

  • Jackson D, Rosenbaum D, Carlisle L, Wells B, Long T, et al. Glutamic acid modification of vincristine-induced toxicity. Proceedings of the American Association of Cancer Research 23: 887, 1982

    Google Scholar 

  • Johnson FL, Bernstein ID, Hartmann JR, et al. Seizures associated with vincristine sulfate therapy. Journal of Pediatrics 82: 699–702, 1973

    Article  PubMed  CAS  Google Scholar 

  • Journey LJ, Burdman J, Whaley A. Ultrastructural studies on the in vivo effects of vincristine sulfate on mouse spinal ganglia. (Abstract 166). Journal of Cell Biology 39: 69a, 1968

    Google Scholar 

  • Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Seminars in Oncology 9: 103–130, 1982

    PubMed  CAS  Google Scholar 

  • Kaufman IA, Kung FH, Koenig HM, Giammona ST. Overdosage with vincristine. Journal of Pediatrics 89: 671–674, 1976

    Article  PubMed  CAS  Google Scholar 

  • Korbitz BC, Davis HL Jr, Ramirez G, Ansfield FJ. Low doses of vincristine (NSC-67574) for malignant disease. Cancer Chemotherapy Reports 53: 249–254, 1969

    CAS  Google Scholar 

  • McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. Journal of Neurology, Neuro-surgery and Psychiatry 32: 297–304, 1969

    Article  CAS  Google Scholar 

  • Moress GR, D’Agostino AW, Jarcho LW. Neuropathy in lymphoblastic leukemia treated with vincristine. Archives of Neurology 16: 377–384, 1967

    Article  PubMed  CAS  Google Scholar 

  • Pratt WB, Ruddon RW. The anticancer drugs, pp. 221–233, Oxford University Press, New York, 1974

    Google Scholar 

  • Rosenthal S, Kaufman S. Vincristine neurotoxicity. Annals of Internal Medicine 80: 733–737, 1974

    PubMed  CAS  Google Scholar 

  • Ryan JR, Emami A. Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia. Cancer 51: 423–425, 1983

    Article  PubMed  CAS  Google Scholar 

  • Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. Neurology 19: 367–374, 1969

    Article  PubMed  CAS  Google Scholar 

  • Scheithauer W, Ludwig H, Maida E. Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Investigational New Drugs 3: 315–318, 1985

    Article  PubMed  CAS  Google Scholar 

  • Schlaepfer WN. Vincristine-induced axonal alterations in rat peripheral nerve. Journal of Neuropathology and Experimental Neurology 30: 488–505, 1971

    Article  PubMed  CAS  Google Scholar 

  • Schochet SS, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. Journal of Neuropathology and Experimental Neurology 27: 645–658, 1968

    Article  PubMed  Google Scholar 

  • Shelanski ML, Wisniewski H. Neurofibrillary degeneration: induced by vincristine therapy. Archives of Neurology 20: 199–206, 1969

    Article  PubMed  CAS  Google Scholar 

  • Shepherd DA, Steuber CP, Starling KA, Fernbach DJ. Accidental intrathecal administration of vincristine. Medical Pediatric Oncology 5: 85–88, 1978

    Article  CAS  Google Scholar 

  • Slater LM, Weiner RA, Serpick AA. Vincristine neurotoxicity with hyponatremia. Cancer 23: 122–125, 1969

    Article  PubMed  CAS  Google Scholar 

  • Slotwiner PS, Song SK, Anderson PJ. Sphenomembranous degeneration of muscle induced by vincristine. Archives of Neurology 15: 172–176, 1966

    Article  PubMed  CAS  Google Scholar 

  • Slyter H, Liwnicz B, Herrick MK, Mason R. Fatal myeloence-phalopathy caused by intrathecal vincristine. Neurology 30: 867–871, 1980

    Article  PubMed  CAS  Google Scholar 

  • Stuart MJ, Cuaso C, Miller M, Oski FA. Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood 45: 315–320, 1975

    PubMed  CAS  Google Scholar 

  • Suskind RM, Brusilow SW, Zehr J. Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level). Journal of Pediatrics 81: 90–92, 1972

    Article  PubMed  CAS  Google Scholar 

  • Tobin W, Sandier SG. Neurophysiologic alterations induced by vincristine. Cancer Chemotherapy Reports 52: 519–526, 1968

    CAS  Google Scholar 

  • Uy QL, Moens TH, Johns RJ, et al. Vincristine neurotoxicity in rodents. Johns Hopkins Medical Journal 121: 349–360, 1967

    PubMed  CAS  Google Scholar 

  • Weiden PL, Wright SE. Vincristine neurotoxicity in patients with Charcot-Marie-Tooth syndrome. New England Journal of Medicine 286: 1369–1370, 1972

    PubMed  CAS  Google Scholar 

  • Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents. New England Journal of Medicine 291: 127–157, 1974

    Article  PubMed  CAS  Google Scholar 

  • Whitelaw DM, Cowan DH, Cassidy FR, Patterson TA. Clinical experience with vincristine. Cancer Chemotherapy Reports 30: 13–20, 1963

    CAS  Google Scholar 

  • Whittaker JA, Griffith IP. Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. British Medical Journal 1: 1251–1272, 1977

    Article  PubMed  CAS  Google Scholar 

  • Wilson L, Anderson KA, Chin D. Nonstoichiometric poisoning of microtubule polymerization: a model for the mechanism of action of the vinca alkaloids, podophyllotoxin and colchicine. In Goldman et al. (Eds) Cold Spring Harbor Conference on Cell Proliferation. III. Cell Motility, pp. 1051–1064, Cold Spring Harbor Laboratory, New York, 1976

    Google Scholar 

  • Wisniewski H, Terry RD, Hirano A. Neurofibrillary pathology. Journal of Neuropathology and Experimental Neurology 29: 163–176, 1970

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, 6723 Bertner, Box 77, Houston, TX, 77030, USA

    Sewa S. Legha

Authors
  1. Sewa S. Legha
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Legha, S.S. Vincristine Neurotoxicity. Medical Toxicology 1, 421–427 (1986). https://doi.org/10.1007/BF03259853

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259853

Keywords

Search

Navigation